Phase 2 trial data shows safety, tolerability and efficacy of imlifidase in GBS patients
Hansa Biopharma today announced positive high-level data from the 15-HMedIdeS-09 phase 2 trial that demonstrated imlifidase was safe and well tolerated when administered prior to standard of care, including rapid…